ClinicalTrials.gg
CompletedNCT06284915Updated Oct 7, 2026Results posted

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

A Phase 3 interventional study of MenACYW conjugate vaccine and MenACYW conjugate vaccine in Meningococcal Immunisation and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 45 sites in 6 countries. Open to participants aged 6 Months to 14 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Updated Oct 7, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
840
Allocation
Randomized
Ages
6 Months to 14 Months
Sex
All
01

Study summary

This study was conducted to support a 2-dose series (1+1 vaccination schedule) for immunization of individuals from 6 months of age. The study was designed to evaluate the non-inferiority of the immunological response of MenACYW conjugate vaccine to Nimenrix® after the completion of the 2-dose series (1+1 vaccination schedule), with the first dose (priming dose) being given at 6-7 months of age to MenACWY- naïve healthy infants and the second dose (booster dose) given at 12-13 months of age. This study also described additional immunogenicity parameters and safety of MenACYW conjugate vaccine and Nimenrix® in the same population of participants.

Read the detailed description

The study duration would be approximately 7 to 8.5 months (at least 7 months per participant).

02

Conditions studied

  • Meningococcal Immunisation
  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
6 Months to 14 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Aged 6 to 7 months on the day of inclusion
  • Participants who were healthy as determined by medical evaluation including medical history, physical examination and judgment of the Investigator

Exclusion Criteria: Participants were excluded from the study if any of the following criteria apply:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks) within the past 3 months
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically
  • At high risk for meningococcal infection during the study (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease)
  • Personal history of Guillain-Barré syndrome
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study intervention(s) used in the study or to a product containing any of the same substances
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
  • Receipt of any vaccine (including COVID-19) and Meningococcal B vaccines) in the 4 weeks preceding the first and second study intervention administration or planned receipt of any vaccine (including COVID-19 and Meningococcal B vaccines) in the 4 weeks following any study intervention administration except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after the study interventions. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination against meningococcal A, C, W, or Y disease with either the trial vaccine or another vaccine (i.e., mono- or quadrivalent meningococcal conjugate vaccine) containing serogroups A, C, Y, or W.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
840 participants (actual)

Study arms

  • Experimental
    Group 1: MenACYW conjugate vaccine

    Participants received the MenACYW conjugate vaccine in a 1+1 dosing schedule (2-dose series). The priming dose (Dose 1) was administered at 6-7 months of age on Day 1, and the booster dose (Dose 2) was administered at 12-13 months of age at Month 6. Each dose consisted of 0.5 milliliter (mL) intramuscular (IM) injection.

    Biological: MenACYW conjugate vaccine

  • Active comparator
    Group 2: Nimenrix®

    Participants received Nimenrix® vaccine as a 1+1 dosing schedule (2-dose series). The priming dose (Dose 1) was administered at 6-7 months of age on Day 1 and, the booster dose (Dose 2) was administered at 12-13 months of age at Month 6. Each dose consisted of 0.5 mL IM injection.

    Biological: MenACYW conjugate vaccine

Interventions

  • BiologicalMenACYW conjugate vaccine

    Pharmaceutical form:Solution for injection (in a single-dose vial)-Route of administration:Intramuscular (IM) injection

    Also known as: MenQuadfi®

  • BiologicalMenACYW conjugate vaccine

    Pharmaceutical form:Solution for injection (powder or cake in a single dose glass vial and a clear and colourless solvent in a pre filled syringe for reconstitution-Route of administration:Intramuscular (IM) injection

    Also known as: Nimenrix®

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Human Complement (hSBA) 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.

    Time frame: At Month 7 (30 days post-dose 2)

  2. Percentage of Participants With Vaccine Seroresponse as Measured By Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:16 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)

Secondary outcomes

  1. Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. The percentage of participants with antibody titers \>=1:8 were assessed. Percentages are rounded to the nearest tenth.

    Time frame: Day 31 (30 days post-dose 1)

  2. Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.

    Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)

  3. Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Pre-dose) and 30 Days After Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)

  4. Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)

  5. Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 1 Compared to Pre-Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 1: priming dose) titer of \>=1:16 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 1: priming dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)

  6. Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.

    Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)

  7. Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)

  8. Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay that utilized hSBA. Participants with hSBA titers \>= 4-fold increase from dose 2 (pre-booster dose) were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)

  9. Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:16 and for a participant with a pre-vaccination titer (pre-dose 2: booster dose) \>=1:8, as a post-vaccination titer (post-dose 2: booster dose) that is at least 4-fold greater than the pre-vaccination titer (pre-dose 2: booster dose). Percentages are rounded to the nearest tenth. Percentages are rounded to the nearest tenth.

    Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)

  10. Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.

    Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)

  11. Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)

  12. Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)

  13. Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement (rSBA) Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.

    Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)

  14. Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, W, and Y Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)

  15. Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)

  16. Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 1 Compared and Pre-Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination titer (post-dose 2: priming dose) of \>=1:32 and for a participant with a pre-vaccination titer (pre-dose 1: priming dose) \>=1:8, as a post-vaccination (post-dose 2: priming dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)

  17. Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.

    Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)

  18. Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)

  19. Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from dose 2 (pre-booster dose) were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)

  20. Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \<1:8 as a post-vaccination (post-dose 2: booster dose) titer of \>=1:32 and for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \>=1:8 as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 2: booster dose) titer. Percentages are rounded to the nearest tenth.

    Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)

  21. Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.

    Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)

  22. Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)

  23. Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)

  24. Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)

    Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:32 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)

  25. Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

    An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination.

    Time frame: Up to 30 minutes after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)

  26. Number of Participants With Solicited Injection Site Reactions and Systemic Reactions

    A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited systemic reactions were systemic AEs observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF.

    Time frame: Up to 7 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)

  27. Number of Participants With Unsolicited Adverse Events

    An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.

    Time frame: Up to 30 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)

  28. Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate.

    Time frame: From first vaccination (Day 1) up to 30 days post last vaccination, approximately 7 months

07

Results

Posted Oct 7, 2026
Limitations and caveats
One participant whose status was recorded as 'completed' in the database should have been classified as 'early termination,' as Visit 4 was not performed in accordance with the protocol. Following discussion with the Principal Investigator, the inconsistency was confirmed. However, since this correction would not impact any study results or conclusions, the Sponsor determined that the finding did not meet the criteria required to unlock the database for correction.

Participant flow

This study was conducted at 47 centers in 6 countries from 19 March 2024 to 14 November 2025.

Participant flow — Overall Study
MilestoneGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Started422418
Safety analysis set (safas)417412
Completed402393
Not completed2025
Withdrew: Lost to follow-up27
Withdrew: Withdrawal by parent/guardian166
Withdrew: Protocol violation25
Withdrew: Adverse event06
Withdrew: Visit 4 not performed as per protocol01

Outcome measures

PrimaryGeometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Human Complement (hSBA) 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.

Time frame:
At Month 7 (30 days post-dose 2)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Human Complement (hSBA) 30 Days After Dose 2 (Booster Dose)
titerGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A170 (143 to 202)203 (168 to 246)
Serogroup C1112 (986 to 1253)302 (258 to 355)
Serogroup Y289 (259 to 323)268 (237 to 303)
Serogroup W275 (240 to 316)299 (258 to 345)
Statistical analysis
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Nimenrix® Vaccine · Geometric mean titer ratio: 0.838 · 95% CI 0.648 to 1.0895% CI of the geometric mean titer ratio calculated using a normal approximation of log-transformed titers.
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Nimenrix® Vaccine · Geometric mean titer ratio: 3.68 · 95% CI 3.01 to 4.4995% CI of the geometric mean titer ratio calculated using a normal approximation of log-transformed titers.
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Nimenrix® Vaccine · Geometric mean titer ratio: 1.08 · 95% CI 0.915 to 1.2795% CI of the geometric mean titer ratio calculated using a normal approximation of log-transformed titers.
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Nimenrix® Vaccine · Geometric mean titer ratio: 0.922 · 95% CI 0.756 to 1.1395% CI of the geometric mean titer ratio calculated using a normal approximation of log-transformed titers.
PrimaryPercentage of Participants With Vaccine Seroresponse as Measured By Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:16 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse as Measured By Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A80.4 (75.2 to 84.9)78.1 (72.5 to 83.0)
Serogroup C98.9 (96.8 to 99.8)96.2 (93.1 to 98.2)
Serogroup Y99.0 (97.0 to 99.8)98.5 (96.3 to 99.6)
Serogroup W97.6 (95.0 to 99.0)97.4 (94.8 to 99.0)
Statistical analysis
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Nimenrix® Vaccine · Difference in percentage of participants: 2.29 · 95% CI -4.58 to 9.1895% CI of the difference in percentage of participants calculated from the Wilson Score method without continuity correction.
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Nimenrix® Vaccine · Difference in percentage of participants: 2.69 · 95% CI -0.03 to 5.8395% CI of the difference in percentage of participants calculated from the Wilson Score method without continuity correction.
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Nimenrix® Vaccine · Difference in percentage of participants: 0.42 · 95% CI -1.74 to 2.7795% CI of the difference in percentage of participants calculated from the Wilson Score method without continuity correction.
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: Nimenrix® Vaccine · Difference in percentage of participants: 0.12 · 95% CI -2.72 to 3.0295% CI of the difference in percentage of participants calculated from the Wilson Score method without continuity correction.
SecondaryPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. The percentage of participants with antibody titers \>=1:8 were assessed. Percentages are rounded to the nearest tenth.

Time frame:
Day 31 (30 days post-dose 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A71.8 (66.9 to 76.4)90.0 (86.4 to 92.9)
Serogroup C99.2 (97.6 to 99.8)89.8 (86.2 to 92.8)
Serogroup Y72.8 (68.0 to 77.3)56.6 (51.3 to 61.8)
Serogroup W50.9 (45.7 to 56.2)24.4 (20.1 to 29.2)
SecondaryGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.

Time frame:
Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Reported as:
Geometric mean · titer
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
titerGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: Day 17.55 (6.04 to 9.42)7.02 (5.64 to 8.73)
Serogroup A: Day 3118.9 (15.8 to 22.6)33.6 (28.9 to 39.1)
Serogroup C: Day 13.12 (2.78 to 3.50)2.81 (2.54 to 3.11)
Serogroup C: Day 31360 (319 to 406)34.7 (30.6 to 39.5)
Serogroup Y: Day 12.06 (2.01 to 2.10)2.14 (2.06 to 2.24)
Serogroup Y: Day 3111.4 (10.1 to 12.8)7.88 (6.95 to 8.93)
Serogroup W: Day 12.19 (2.06 to 2.33)2.20 (2.07 to 2.32)
Serogroup W: Day 316.64 (5.87 to 7.52)3.82 (3.42 to 4.28)
SecondaryPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Pre-dose) and 30 Days After Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Pre-dose) and 30 Days After Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: >=1:4; Day 139.3 (34.2 to 44.6)35.7 (30.7 to 41.0)
Serogroup A: >=1:4; Day 3185.4 (81.3 to 88.8)95.0 (92.2 to 97.0)
Serogroup A: >=1:8; Day 127.5 (23.0 to 32.5)27.1 (22.6 to 32.1)
Serogroup A: >=1:8; Day 3171.8 (66.9 to 76.4)90.0 (86.4 to 92.9)
Serogroup C: >=1:4; Day 119.1 (15.1 to 23.6)15.6 (11.9 to 19.9)
Serogroup C: >=1:4; Day 3199.4 (98.0 to 99.9)93.5 (90.4 to 95.8)
Serogroup C: >=1:8; Day 114.5 (11.0 to 18.7)11.3 (8.1 to 15.1)
Serogroup C: >=1:8; Day 3199.2 (97.6 to 99.8)89.8 (86.2 to 92.8)
Serogroup Y: >=1:4; Day 12.3 (1.0 to 4.4)3.7 (2.0 to 6.3)
Serogroup Y: >=1:4; Day 3183.7 (79.5 to 87.3)72.8 (67.9 to 77.4)
Serogroup Y: >=1:8; Day 11.4 (0.5 to 3.3)2.9 (1.4 to 5.2)
Serogroup Y: >=1:8; Day 3172.8 (68.0 to 77.3)56.6 (51.3 to 61.8)
Serogroup W: >=1:4; Day 13.7 (2.0 to 6.2)4.9 (2.9 to 7.7)
Serogroup W: >=1:4; Day 3162.1 (56.9 to 67.0)39.3 (34.2 to 44.6)
Serogroup W: >=1:8; Day 12.3 (1.0 to 4.4)2.6 (1.2 to 4.8)
Serogroup W: >=1:8; Day 3150.9 (45.7 to 56.2)24.4 (20.1 to 29.2)
SecondaryPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A44.8 (39.5 to 50.1)64.6 (59.3 to 69.6)
Serogroup C96.8 (94.3 to 98.4)82.7 (78.3 to 86.6)
Serogroup Y71.5 (66.5 to 76.2)54.0 (48.6 to 59.4)
Serogroup W49.7 (44.4 to 55.1)24.3 (19.9 to 29.1)
SecondaryPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 1 Compared to Pre-Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 1: priming dose) titer of \>=1:16 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 1: priming dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 1 Compared to Pre-Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A31.4 (26.6 to 36.6)55.4 (50.1 to 60.7)
Serogroup C96.5 (94.0 to 98.2)78.0 (73.2 to 82.3)
Serogroup Y49.9 (44.5 to 55.2)35.0 (29.9 to 40.3)
Serogroup W31.7 (26.9 to 36.9)14.5 (10.9 to 18.6)
SecondaryGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.

Time frame:
Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Reported as:
Geometric mean · titer
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
titerGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: Month 620.8 (16.9 to 25.6)26.4 (21.3 to 32.9)
Serogroup A: Month 7170 (143 to 202)203 (168 to 246)
Serogroup C: Month 6227 (197 to 263)29.6 (25.1 to 34.9)
Serogroup C: Month 71112 (986 to 1253)302 (258 to 355)
Serogroup Y: Month 660.0 (53.1 to 67.8)23.7 (20.8 to 27.0)
Serogroup Y: Month 7289 (259 to 323)268 (237 to 303)
Serogroup W: Month 645.5 (39.5 to 52.3)26.1 (22.5 to 30.4)
Serogroup W: Month 7275 (240 to 316)299 (258 to 345)
SecondaryPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: >=1:4; Month 685.3 (80.6 to 89.2)86.2 (81.5 to 90.1)
Serogroup A: >=1:4; Month 798.3 (96.0 to 99.4)97.1 (94.3 to 98.7)
Serogroup A: >=1:8; Month 671.0 (65.3 to 76.2)76.2 (70.7 to 81.2)
Serogroup A: >=1:8; Month 796.2 (93.2 to 98.1)95.6 (92.4 to 97.7)
Serogroup C: >=1:4; Month 699.7 (98.1 to 100)93.1 (89.4 to 95.8)
Serogroup C: >=1:4; Month 7100 (98.7 to 100)98.9 (96.9 to 99.8)
Serogroup C: >=1:8; Month 699.7 (98.1 to 100)86.5 (81.9 to 90.3)
Serogroup C: >=1:8; Month 7100 (98.7 to 100)98.2 (95.9 to 99.4)
Serogroup Y: >=1:4; Month 699.3 (97.5 to 99.9)96.1 (93.1 to 98.0)
Serogroup Y: >=1:4; Month 7100 (98.8 to 100)100 (98.7 to 100)
Serogroup Y: >=1:8; Month 698.3 (96.0 to 99.4)90.0 (85.9 to 93.3)
Serogroup Y: >=1:8; Month 799.7 (98.2 to 100)99.3 (97.5 to 99.9)
Serogroup W: >=1:4; Month 697.9 (95.6 to 99.2)94.6 (91.2 to 96.9)
Serogroup W: >=1:4; Month 798.0 (95.7 to 99.3)99.7 (98.1 to 100)
Serogroup W: >=1:8; Month 693.4 (90.0 to 96.0)89.5 (85.3 to 92.9)
Serogroup W: >=1:8; Month 798.0 (95.7 to 99.3)99.0 (97.0 to 99.8)
SecondaryPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay that utilized hSBA. Participants with hSBA titers \>= 4-fold increase from dose 2 (pre-booster dose) were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A70.2 (64.3 to 75.6)72.9 (67.0 to 78.3)
Serogroup C69.1 (63.3 to 74.5)86.6 (81.9 to 90.4)
Serogroup Y68.6 (62.9 to 74.0)91.0 (87.1 to 94.1)
Serogroup W78.1 (72.9 to 82.8)88.4 (84.0 to 91.9)
SecondaryPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:16 and for a participant with a pre-vaccination titer (pre-dose 2: booster dose) \>=1:8, as a post-vaccination titer (post-dose 2: booster dose) that is at least 4-fold greater than the pre-vaccination titer (pre-dose 2: booster dose). Percentages are rounded to the nearest tenth. Percentages are rounded to the nearest tenth.

Time frame:
Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A69.8 (63.9 to 75.3)72.5 (66.6 to 77.9)
Serogroup C69.1 (63.3 to 74.5)85.8 (81.1 to 89.8)
Serogroup Y68.6 (62.9 to 74.0)91.0 (87.1 to 94.1)
Serogroup W77.8 (72.5 to 82.4)88.4 (84.0 to 91.9)
SecondaryGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA and the results were expressed as geometric mean titers.

Time frame:
Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Reported as:
Geometric mean · titer
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
titerGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: Day 16.62 (5.27 to 8.31)6.82 (5.36 to 8.67)
Serogroup A: Month 7170 (143 to 202)203 (168 to 246)
Serogroup C: Day 12.97 (2.63 to 3.36)2.80 (2.51 to 3.12)
Serogroup C: Month 71112 (986 to 1253)302 (258 to 355)
Serogroup Y: Day 12.06 (2.01 to 2.12)2.11 (2.03 to 2.20)
Serogroup Y: Month 7289 (259 to 323)268 (237 to 303)
Serogroup W: Day 12.06 (2.01 to 2.11)2.15 (2.03 to 2.28)
Serogroup W: Month 7275 (240 to 316)299 (258 to 345)
SecondaryPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 1:4 and \>= 1:8 were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: >=1:4; Day 137.0 (31.4 to 42.8)36.0 (30.3 to 41.9)
Serogroup A: >=1:4; Month 798.3 (96.0 to 99.4)97.1 (94.3 to 98.7)
Serogroup A: >=1:8; Day 126.4 (21.4 to 31.8)26.6 (21.5 to 32.2)
Serogroup A: >=1:8; Month 796.2 (93.2 to 98.1)95.6 (92.4 to 97.7)
Serogroup C: >=1:4; Day 116.7 (12.6 to 21.6)16.5 (12.3 to 21.4)
Serogroup C: >=1:4; Month 7100 (98.7 to 100)98.9 (96.9 to 99.8)
Serogroup C: >=1:8; Day 112.9 (9.2 to 17.3)11.0 (7.5 to 15.3)
Serogroup C: >=1:8; Month 7100 (98.7 to 100)98.2 (95.9 to 99.4)
Serogroup Y: >=1:4; Day 12.1 (0.8 to 4.4)3.3 (1.5 to 6.1)
Serogroup Y: >=1:4; Month 7100 (98.8 to 100)100 (98.7 to 100)
Serogroup Y: >=1:8; Day 11.4 (0.4 to 3.5)2.5 (1.0 to 5.2)
Serogroup Y: >=1:8; Month 799.7 (98.2 to 100)99.3 (97.5 to 99.9)
Serogroup W: >=1:4; Day 12.4 (1.0 to 4.9)4.0 (2.0 to 7.0)
Serogroup W: >=1:4; Month 798.0 (95.7 to 99.3)99.7 (98.1 to 100)
Serogroup W: >=1:8; Day 11.0 (0.2 to 3.0)1.4 (0.4 to 3.7)
Serogroup W: >=1:8; Month 798.0 (95.7 to 99.3)99.0 (97.0 to 99.8)
SecondaryPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the hSBA. Participants with hSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A81.5 (76.3 to 85.9)79.6 (74.2 to 84.3)
Serogroup C98.9 (96.8 to 99.8)96.6 (93.6 to 98.4)
Serogroup Y99.0 (97.0 to 99.8)98.9 (96.8 to 99.8)
Serogroup W97.9 (95.5 to 99.2)98.2 (95.8 to 99.4)
SecondaryGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement (rSBA) Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.

Time frame:
Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Reported as:
Geometric mean · titer
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement (rSBA) Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
titerGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: Day 12.30 (1.89 to 2.79)2.58 (2.02 to 3.29)
Serogroup A: Day 31162 (89.2 to 293)926 (630 to 1362)
Serogroup C: Day 12.11 (1.89 to 2.36)2.02 (1.98 to 2.05)
Serogroup C: Day 311195 (913 to 1563)179 (126 to 253)
Serogroup Y: Day 15.33 (3.48 to 8.15)6.26 (3.99 to 9.82)
Serogroup Y: Day 31602 (405 to 895)576 (412 to 804)
Serogroup W: Day 12.21 (1.91 to 2.57)2.13 (1.88 to 2.40)
Serogroup W: Day 311312 (902 to 1909)475 (299 to 753)
SecondaryPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, W, and Y Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, W, and Y Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: >=1:8; Day 12.7 (0.3 to 9.3)5.1 (1.4 to 12.5)
Serogroup A: >=1:8; Day 3182.5 (72.4 to 90.1)97.6 (91.6 to 99.7)
Serogroup A: >=1:128; Day 12.7 (0.3 to 9.3)5.1 (1.4 to 12.5)
Serogroup A: >=1:128; Day 3163.8 (52.2 to 74.2)90.4 (81.9 to 95.7)
Serogroup C: >=1:8; Day 11.3 (0 to 7.2)0 (0 to 4.6)
Serogroup C: >=1:8; Day 31100 (95.5 to 100)94.0 (86.5 to 98.0)
Serogroup C: >=1:128; Day 11.3 (0 to 7.2)0 (0 to 4.6)
Serogroup C: >=1:128; Day 3198.8 (93.3 to 100)75.9 (65.3 to 84.6)
Serogroup Y: >=1:8; Day 124.0 (14.9 to 35.3)26.6 (17.3 to 37.7)
Serogroup Y: >=1:8; Day 3195.1 (87.8 to 98.6)96.4 (89.8 to 99.2)
Serogroup Y: >=1:128; Day 114.7 (7.6 to 24.7)17.7 (10.0 to 27.9)
Serogroup Y: >=1:128; Day 3191.4 (83.0 to 96.5)96.4 (89.8 to 99.2)
Serogroup W: >=1:8; Day 12.7 (0.3 to 9.3)1.3 (0 to 6.9)
Serogroup W: >=1:8; Day 31100 (95.5 to 100)92.8 (84.9 to 97.3)
Serogroup W: >=1:128; Day 11.3 (0 to 7.2)1.3 (0 to 6.9)
Serogroup W: >=1:128; Day 31100 (95.5 to 100)90.4 (81.9 to 95.7)
SecondaryPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A78.4 (67.3 to 87.1)92.4 (84.2 to 97.2)
Serogroup C100 (95.2 to 100)93.7 (85.8 to 97.9)
Serogroup Y85.3 (75.3 to 92.4)82.3 (72.1 to 90.0)
Serogroup W100 (95.2 to 100)92.4 (84.2 to 97.2)
SecondaryPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 1 Compared and Pre-Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination titer (post-dose 2: priming dose) of \>=1:32 and for a participant with a pre-vaccination titer (pre-dose 1: priming dose) \>=1:8, as a post-vaccination (post-dose 2: priming dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 1 Compared and Pre-Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A63.5 (51.5 to 74.4)92.4 (84.2 to 97.2)
Serogroup C98.7 (92.8 to 100)92.4 (84.2 to 97.2)
Serogroup Y85.3 (75.3 to 92.4)82.3 (72.1 to 90.0)
Serogroup W100 (95.2 to 100)92.4 (84.2 to 97.2)
SecondaryGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.

Time frame:
Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Reported as:
Geometric mean · titer
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
titerGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: Month 642.7 (20.6 to 88.6)67.2 (35.1 to 129)
Serogroup A: Month 71616 (1274 to 2049)1827 (1431 to 2332)
Serogroup C: Month 6209 (136 to 320)17.1 (11.4 to 25.7)
Serogroup C: Month 71819 (1376 to 2404)473 (345 to 649)
Serogroup Y: Month 6151 (100 to 227)90.5 (57.9 to 142)
Serogroup Y: Month 7943 (737 to 1207)882 (665 to 1169)
Serogroup W: Month 6136 (89.1 to 207)53.3 (34.1 to 83.3)
Serogroup W: Month 71530 (1176 to 1989)1015 (767 to 1343)
SecondaryPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: >=1:8; Month 655.4 (42.5 to 67.7)64.8 (52.5 to 75.8)
Serogroup A: >=1:8; Month 7100 (95.3 to 100)100 (95.4 to 100)
Serogroup A: >=1:128; Month 649.2 (36.6 to 61.9)56.3 (44.0 to 68.1)
Serogroup A: >=1:128; Month 7100 (95.3 to 100)98.7 (93.1 to 100)
Serogroup C: >=1:8; Month 694.1 (85.6 to 98.4)68.1 (56.0 to 78.6)
Serogroup C: >=1:8; Month 7100 (95.3 to 100)98.7 (93.1 to 100)
Serogroup C: >=1:128; Month 677.9 (66.2 to 87.1)19.4 (11.1 to 30.5)
Serogroup C: >=1:128; Month 7100 (95.3 to 100)92.4 (84.2 to 97.2)
Serogroup Y: >=1:8; Month 692.6 (83.7 to 97.6)88.6 (78.7 to 94.9)
Serogroup Y: >=1:8; Month 7100 (95.3 to 100)98.7 (93.1 to 100)
Serogroup Y: >=1:128; Month 673.5 (61.4 to 83.5)57.1 (44.7 to 68.9)
Serogroup Y: >=1:128; Month 798.7 (92.9 to 100)97.5 (91.2 to 99.7)
Serogroup W: >=1:8; Month 692.8 (83.9 to 97.6)80.6 (69.5 to 88.9)
Serogroup W: >=1:8; Month 7100 (95.3 to 100)100 (95.4 to 100)
Serogroup W: >=1:128; Month 668.1 (55.8 to 78.8)52.8 (40.7 to 64.7)
Serogroup W: >=1:128; Month 7100 (95.3 to 100)96.2 (89.3 to 99.2)
SecondaryPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from dose 2 (pre-booster dose) were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A80.0 (68.2 to 88.9)77.5 (66.0 to 86.5)
Serogroup C80.9 (69.5 to 89.4)88.9 (79.3 to 95.1)
Serogroup Y67.6 (55.2 to 78.5)75.7 (64.0 to 85.2)
Serogroup W89.9 (80.2 to 95.8)87.5 (77.6 to 94.1)
SecondaryPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \<1:8 as a post-vaccination (post-dose 2: booster dose) titer of \>=1:32 and for a participant with a pre-vaccination (pre-dose 2: booster dose) titer \>=1:8 as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 2: booster dose) titer. Percentages are rounded to the nearest tenth.

Time frame:
Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A80.0 (68.2 to 88.9)77.5 (66.0 to 86.5)
Serogroup C80.9 (69.5 to 89.4)87.5 (77.6 to 94.1)
Serogroup Y67.6 (55.2 to 78.5)75.7 (64.0 to 85.2)
Serogroup W89.9 (80.2 to 95.8)87.5 (77.6 to 94.1)
SecondaryGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA and the results were expressed as geometric mean titers.

Time frame:
Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Reported as:
Geometric mean · titer
Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
titerGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: Day 12.34 (1.88 to 2.90)2.47 (1.94 to 3.15)
Serogroup A: Month 71616 (1274 to 2049)1827 (1431 to 2332)
Serogroup C: Day 12.13 (1.88 to 2.41)2.02 (1.98 to 2.06)
Serogroup C: Month 71819 (1376 to 2404)473 (345 to 649)
Serogroup Y: Day 14.72 (3.06 to 7.29)5.24 (3.37 to 8.14)
Serogroup Y: Month 7943 (737 to 1207)882 (665 to 1169)
Serogroup W: Day 12.08 (1.92 to 2.26)2.00 (NA to NA)
Serogroup W: Month 71530 (1176 to 1989)1015 (767 to 1343)
SecondaryPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 1:8 and \>= 1:128 were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A: >=1:8; Day 13.0 (0.4 to 10.4)4.2 (0.9 to 11.7)
Serogroup A: >=1:8; Month 7100 (95.3 to 100)100 (95.4 to 100)
Serogroup A: >=1:128; Day 13.0 (0.4 to 10.4)4.2 (0.9 to 11.7)
Serogroup A: >=1:128; Month 7100 (95.3 to 100)98.7 (93.1 to 100)
Serogroup C: >=1:8; Day 11.5 (0 to 8.0)0 (0 to 5.0)
Serogroup C: >=1:8; Month 7100 (95.3 to 100)98.7 (93.1 to 100)
Serogroup C: >=1:128; Day 11.5 (0 to 8.0)0 (0 to 5.0)
Serogroup C: >=1:128; Month 7100 (95.3 to 100)92.4 (84.2 to 97.2)
Serogroup Y: >=1:8; Day 120.9 (11.9 to 32.6)23.6 (14.4 to 35.1)
Serogroup Y: >=1:8; Month 7100 (95.3 to 100)98.7 (93.1 to 100)
Serogroup Y: >=1:128; Day 111.9 (5.3 to 22.2)15.3 (7.9 to 25.7)
Serogroup Y: >=1:128; Month 798.7 (92.9 to 100)97.5 (91.2 to 99.7)
Serogroup W: >=1:8; Day 11.5 (0 to 8.0)0 (0 to 5.0)
Serogroup W: >=1:8; Month 7100 (95.3 to 100)100 (95.4 to 100)
Serogroup W: >=1:128; Day 10 (0 to 5.4)0 (0 to 5.0)
Serogroup W: >=1:128; Month 7100 (95.3 to 100)96.2 (89.3 to 99.2)
SecondaryPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. Participants with rSBA titers \>= 4-fold increase from baseline (pre-vaccination) were analyzed. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A98.5 (92.0 to 100)98.6 (92.5 to 100)
Serogroup C100 (94.6 to 100)97.2 (90.3 to 99.7)
Serogroup Y92.5 (83.4 to 97.5)91.7 (82.7 to 96.9)
Serogroup W100 (94.6 to 100)100 (95.0 to 100)
SecondaryPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)

Functional meningococcal antibody activity against serogroups A, C, W, and Y was measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse was defined for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \<1:8, as a post-vaccination (post-dose 2: booster dose) titer of \>=1:32 and for a participant with a pre-vaccination (pre-dose 1: priming dose) titer \>=1:8, as a post-vaccination (post-dose 2: booster dose) titer that is at least 4-fold greater than the pre-vaccination (pre-dose 1: priming dose) titer. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Serogroup A98.5 (92.0 to 100)98.6 (92.5 to 100)
Serogroup C100 (94.6 to 100)95.8 (88.3 to 99.1)
Serogroup Y92.5 (83.4 to 97.5)91.7 (82.7 to 96.9)
Serogroup W100 (94.6 to 100)100 (95.0 to 100)
SecondaryNumber of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination.

Time frame:
Up to 30 minutes after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
Reported as:
Count of participants · Participants
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
ParticipantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)21
SecondaryNumber of Participants With Solicited Injection Site Reactions and Systemic Reactions

A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited systemic reactions were systemic AEs observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF.

Time frame:
Up to 7 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions and Systemic Reactions
ParticipantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Solicited injection site reaction234245
Solicited systemic reaction312326
SecondaryNumber of Participants With Unsolicited Adverse Events

An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.

Time frame:
Up to 30 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events
ParticipantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
Number of Participants With Unsolicited Adverse Events246243
SecondaryNumber of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate.

Time frame:
From first vaccination (Day 1) up to 30 days post last vaccination, approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
SAEs2120
AESIs32

Adverse events

Collected over AEs, SAEs, and all-cause mortality (deaths) were collected from vaccination (Day 1) up to 30 days post last vaccination, approximately 7 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: MenACYW Conjugate Vaccine0/417 (0%)21/417 (5%)347/417 (83.2%)
Group 2: Nimenrix® Vaccine1/412 (0.2%)20/412 (4.9%)370/412 (89.8%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
PneumoniaInfections and infestations4/4173/412
Febrile ConvulsionNervous system disorders3/4171/412
ConcussionInjury, poisoning and procedural complications1/4172/412
BronchitisInfections and infestations2/4171/412
Upper Respiratory Tract InfectionInfections and infestations2/4170/412
Bronchitis ViralInfections and infestations0/4171/412
Covid-19Infections and infestations1/4171/412
Exanthema SubitumInfections and infestations1/4171/412
LaryngitisInfections and infestations1/4171/412
Parainfluenzae Virus InfectionInfections and infestations0/4171/412
Most frequent other events
Showing 10 of 14
Most frequent other events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® Vaccine
IrritabilityPsychiatric disorders253/417263/412
CryingGeneral disorders228/417240/412
Injection Site ErythemaGeneral disorders160/417182/412
SomnolenceNervous system disorders149/417175/412
Injection Site PainGeneral disorders159/417155/412
Decreased AppetiteMetabolism and nutrition disorders141/417157/412
Injection Site SwellingGeneral disorders89/41797/412
PyrexiaGeneral disorders86/41786/412
VomitingGastrointestinal disorders86/41770/412
Upper Respiratory Tract InfectionInfections and infestations57/41753/412

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(months)Group 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® VaccineTotal
Mean6.5 ± 0.506.5 ± 0.506.5 ± 0.50
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® VaccineTotal
Female200182382
Male222236458
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: Nimenrix® VaccineTotal
American Indian or Alaska Native000
Asian279
Black or African American011
Native Hawaiian or Other Pacific Islander000
White417407824
Multiple123
Not Reported101
Unknown112
08

Study locations

45 sites
  • Investigational Site Number : 2030002
    České Budějovice, 370 06, Czechia
  • Investigational Site Number: 2030001
    České Budějovice, Czechia
  • Investigational Site Number: 2030005
    Prague, Czechia
  • Investigational Site Number: 2080007
    Aalborg, Denmark
  • Investigational Site Number: 2080004
    Aarhus, Denmark
  • Investigational Site Number: 2080006
    Herlev, Denmark
  • Investigational Site Number : 2080005
    Hjørring, 9800, Denmark
  • Investigational Site Number: 2080002
    Odense, Denmark
  • Investigational Site Number: 2080001
    Zeeland, Denmark
  • Investigational Site Number: 2460005
    Espoo, Finland
  • Investigational Site Number: 2460002
    Helsinki, Finland
  • Investigational Site Number: 2460011
    Helsinki, Finland
  • Investigational Site Number: 2460006
    Jaarvenpa, Finland
  • Investigational Site Number : 2460003
    Kokkola, 67100, Finland
  • Investigational Site Number: 2460007
    Oulu, Finland
  • Investigational Site Number: 2460004
    Tampere, Finland
  • Investigational Site Number: 2460012
    Turku, Finland
  • Investigational Site Number: 2760007
    Erfurt, Germany
  • Investigational Site Number: 2760004
    Herxheim, Germany
  • Investigational Site Number: 2760003
    Hürth, Germany
  • Investigational Site Number: 2760001
    Mönchengladbach, Germany
  • Investigational Site Number: 2760011
    Mönchengladbach, Germany
  • Investigational Site Number: 2760005
    Schönau am Königssee, Germany
  • Investigational Site Number: 2760008
    Schweigen-Rechtenbach, Germany
  • Investigational Site Number: 2760010
    Wolfsburg, Germany
  • Investigational Site Number : 2760009
    Worms, 67550, Germany
  • Investigational Site Number : 6160001
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-079, Poland
  • Investigational Site Number: 6160003
    Bydgoszcz, Poland
  • Investigational Site Number: 6160008
    Bydgoszcz, Poland
  • Investigational Site Number: 6160017
    Bydgoszcz, Poland
  • Investigational Site Number: 6160015
    Krakow, Poland
  • Investigational Site Number: 6160021
    Krakow, Poland
  • Investigational Site Number: 6160012
    Luboń, Poland
  • Investigational Site Number: 6160011
    Siemianowice Śląskie, Poland
  • Investigational Site Number: 6160007
    Torun, Poland
  • Investigational Site Number: 6160014
    Trzebnica, Poland
  • Investigational Site Number: 6160022
    Warsaw, Poland
  • Investigational Site Number: 6160010
    Wroclav, Poland
  • Investigational Site Number: 6160002
    Wroclaw, Poland
  • Investigational Site Number: 6160016
    Łęczna, Poland
  • Investigational Site Number: 6160004
    Łomianki, Poland
  • Investigational Site Number : 6420001
    Bucharest, 011025, Romania
  • Investigational Site Number : 6420003
    Bucharest, 021105, Romania
  • Investigational Site Number: 6420002
    Bucharest, Romania
  • Investigational Site Number: 6420005
    Calarasi, Romania
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Nov 2025, 19 months.

Results were first posted in Oct 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 29, 2024
StartActual
Mar 19, 2024
Primary completionActual
Nov 14, 2025
CompletionActual
Nov 14, 2025
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedParticipants who arewere healthy as determined by medical evaluation including medical history, physical examination and judgment of the Investigator
  • EditedExclusion Criteria: Participants arewere excluded from the study if any of the following criteria apply:
Oct 7, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedGeometric mean titersMean Titers (GMTs) of Antibodies against meningococcal serogroupsAgainst Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Human Complement (hSBA) 30 Days After Dose 2 (Booster Dose)Time frame: 30 days after dose 2 (booster dose) (+14 days) → At Month 7 (30 days post-dose 2)
  • ChangedBefore Vaccine Seroresponse to meningococcal serogroups A, C, W and Y assessed by hSBANow Percentage of Participants With Vaccine Seroresponse as Measured By Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)Time frame: 30 days after dose 2 (booster dose) (+14 days) → Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
Oct 7, 2026
Documents
Secondary outcomes
5 edited, 23 added, 2 removed, 6 more
What changed in the outcomes
  • EditedhSBA antibody titers ≥ Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:8 against meningococcal serogroupsAgainst Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 1 (Priming Dose)Time frame: 30 days after dose 1 (priming dose) (+14 days) → Day 31 (30 days post-dose 1)
  • EditedNumber of participants with immediate adverse eventsParticipants With Immediate Unsolicited Systemic Adverse Events (AEs)Time frame: Within 30 minutes after each vaccination → Up to 30 minutes after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
  • EditedNumber of participants with solicited injection site reactions or systemic reactionsParticipants With Solicited Injection Site Reactions and Systemic ReactionsTime frame: Within 7 days after each vaccination → Up to 7 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
  • EditedNumber of participants with unsolicited AEsParticipants With Unsolicited Adverse EventsTime frame: Up to 30 days after each vaccination → Up to 30 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
  • EditedNumber of participants with serious adverse eventsParticipants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)Time frame: From baseline to up to 7 months → From first vaccination (Day 1) up to 30 days post last vaccination, approximately 7 months
  • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
  • AddedPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Pre-dose) and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
  • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
  • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 1 Compared to Pre-Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
  • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
  • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
  • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement (rSBA) Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
  • AddedPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, W, and Y Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
  • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
  • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 1 Compared and Pre-Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
  • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
  • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
  • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
  • RemovedhSBA antibody titers against meningococcal serogroups A, C, W and YTime frame: For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days)
  • RemovedhSBA antibody titers ≥ several pre-defined thresholds against meningococcal serogroups A, C, W and YTime frame: For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days
  • …and 6 more, on the record history on ClinicalTrials.gov ↗
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedParticipants who arewere healthy as determined by medical evaluation including medical history, physical examination and judgment of the Investigator
    • EditedExclusion Criteria: Participants arewere excluded from the study if any of the following criteria apply:
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedGeometric mean titersMean Titers (GMTs) of Antibodies against meningococcal serogroupsAgainst Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Human Complement (hSBA) 30 Days After Dose 2 (Booster Dose)Time frame: 30 days after dose 2 (booster dose) (+14 days) → At Month 7 (30 days post-dose 2)
    • ChangedBefore Vaccine Seroresponse to meningococcal serogroups A, C, W and Y assessed by hSBANow Percentage of Participants With Vaccine Seroresponse as Measured By Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)Time frame: 30 days after dose 2 (booster dose) (+14 days) → Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
    Secondary outcomes 5 edited, 23 added, 2 removed, 6 more
    What changed in the outcomes
    • EditedhSBA antibody titers ≥ Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:8 against meningococcal serogroupsAgainst Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 1 (Priming Dose)Time frame: 30 days after dose 1 (priming dose) (+14 days) → Day 31 (30 days post-dose 1)
    • EditedNumber of participants with immediate adverse eventsParticipants With Immediate Unsolicited Systemic Adverse Events (AEs)Time frame: Within 30 minutes after each vaccination → Up to 30 minutes after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
    • EditedNumber of participants with solicited injection site reactions or systemic reactionsParticipants With Solicited Injection Site Reactions and Systemic ReactionsTime frame: Within 7 days after each vaccination → Up to 7 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
    • EditedNumber of participants with unsolicited AEsParticipants With Unsolicited Adverse EventsTime frame: Up to 30 days after each vaccination → Up to 30 days after each vaccination (Dose 1 on Day 1 and Dose 2 on Month 6)
    • EditedNumber of participants with serious adverse eventsParticipants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)Time frame: From baseline to up to 7 months → From first vaccination (Day 1) up to 30 days post last vaccination, approximately 7 months
    • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
    • AddedPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Pre-dose) and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
    • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
    • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W and Y 30 Days After Dose 1 Compared to Pre-Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
    • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assay Using Human Complement Against Meningococcal Serogroups A, C, W, and Y 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
    • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assay Using Human Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 and >=1:8 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assay Using Human Complement Antibody Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
    • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement (rSBA) Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
    • AddedPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, W, and Y Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
    • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 1 and 30 Days After Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
    • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 1 Compared and Pre-Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Day 31 (30 days post-dose 1)
    • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose 2 and 30 Days After Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 Compared to Pre-Dose 2 (Booster Dose)Time frame: Month 6 (pre-dose 2) and Month 7 (30 days post-dose 2)
    • AddedGeometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y Measured by Serum Bactericidal Assays Using Baby Rabbit Complement Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With Serum Bactericidal Assays Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Before Dose 1 (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With >=4-Fold Rise in Serum Bactericidal Assays Using Baby Rabbit Complement Titers From Before Dose (Priming Dose) and 30 Days After Dose 2 (Booster Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
    • AddedPercentage of Participants With Vaccine Seroresponse as Measured by Serum Bactericidal Assays Using Baby Rabbit Complement 30 Days After Dose 2 (Booster Dose) Compared to Pre-Dose 1 (Priming Dose)Time frame: Day 1 (pre-dose 1) and Month 7 (30 days post-dose 2)
    • RemovedhSBA antibody titers against meningococcal serogroups A, C, W and YTime frame: For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days)
    • RemovedhSBA antibody titers ≥ several pre-defined thresholds against meningococcal serogroups A, C, W and YTime frame: For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days
    • …and 6 more, on the record history on ClinicalTrials.gov ↗
    + 7 other changes: identifiers, verification date, description, design details, arm descriptions, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06284915
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Mar 19, 2024
Primary completion
Nov 14, 2025
Completion
Nov 14, 2025
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion